Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/9684
Title: Insulin-like growth factor binding protein-6 and CCI-779, an ester analogue of rapamycin, additively inhibit rhabdomyosarcoma growth.
Authors: Gallicchio, M A;van Sinderen, M;Bach, Leon A
Affiliation: Department of Medicine, University of Melbourne, Austin Hospital, Studley Rd, Heidelberg, Victoria, 3084, Australia.
Issue Date: 12-Nov-2003
Citation: Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Me´tabolisme; 35(11-12): 822-7
Abstract: Rhabdomyosarcomas secrete high levels of insulin-like growth factor-II, suggesting this autocrine growth factor plays a major role in the unregulated growth of this childhood cancer. Treatment of Rh30 rhabdomyosarcoma cells with insulin-like growth factor binding protein-6 (IGFBP-6; 1000 ng/ml), which binds insulin-like growth factor-II with high affinity, inhibited growth in vitro (p < 0.001). Co-incubation of cells with rapamycin (1.56 ng/ml), an inhibitor of p70 S6 kinase, and IGFBP-6 (200 ng/ml) resulted in a significant reduction in Rh30 cell number compared to rapamycin or IGFBP-6 alone (p < 0.05 for both). Co-treatment of Rh30 cells with CCI-779 (5 and 50 ng/ml), an ester analogue of rapamycin, and IGFBP-6 (200 or 1000 ng/ml) also inhibited growth in vitro relative to CCI-779 alone (p < 0.01 and p < 0.001, respectively). In a nude mouse model, xenografts of Rh30 cells transfected with a recombinant vector encoding IGFBP-6 (phBP6-E3) showed delayed growth relative to vector control xenografts (27 days vs. 19 days to reach an average tumour volume of 0.5 cm (3); p < 0.001). Treatment with CCI-779 (10 mg/kg) of mice inoculated with vector control xenografts, also delayed growth (to 31 days; p = 0.0055) relative to untreated mice with vector control xenografts. Co-treatment with CCI-779 (10 mg/kg) reduced phBP6-E3 transfected xenograft growth even further (to 45 days) compared to vector control xenografts (p < 0.001, day 33). CCI-779 thus acts additively with IGFBP-6 to reduce rhabdomyosarcoma growth both in vitro and in vivo.
Internal ID Number: 14710364
URI: http://ahro.austin.org.au/austinjspui/handle/1/9684
DOI: 10.1055/s-2004-814153
URL: http://www.ncbi.nlm.nih.gov/pubmed/14710364
Type: Journal Article
Subjects: Animals
Cell Division.drug effects
Cell Line
Cell Line, Tumor
Humans
Insulin-Like Growth Factor Binding Protein 6.pharmacology
Kidney
Kinetics
Mice
Mice, Nude
Recombinant Proteins.pharmacology
Rhabdomyosarcoma.pathology
Sirolimus.analogs & derivatives.pharmacology
Transplantation, Heterologous
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.